Research programme: cell-based influenza virus vaccines - Crucell

Drug Profile

Research programme: cell-based influenza virus vaccines - Crucell

Alternative Names: FluCell; FluCell - Plus (Seasonal Plus); UniFlu

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Crucell
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza virus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in Netherlands (Parenteral)
  • 06 Sep 2013 Isconova is now called Novavax AB
  • 22 Aug 2013 Isconova has been acquired by Novavax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top